Similar Articles |
|
The Motley Fool November 4, 2009 Brian Orelli |
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. |
The Motley Fool July 27, 2004 Brian Gorman |
Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans. |
The Motley Fool February 25, 2009 Brian Orelli |
The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers. |
The Motley Fool April 19, 2011 Bryan White |
Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies. |
The Motley Fool April 27, 2005 Brian Gorman |
Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back. |
The Motley Fool April 30, 2008 Brian Orelli |
Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs. |
The Motley Fool December 6, 2007 Selena Maranjian |
Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall. |
BusinessWeek March 7, 2005 Amy Barrett |
A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities. |
The Motley Fool February 16, 2005 Brian Gorman |
Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies? |
The Motley Fool July 25, 2011 Brian Orelli |
Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion. |
The Motley Fool February 28, 2005 Brian Gorman |
Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending. |
The Motley Fool April 29, 2010 Brian Orelli |
A Prescription to Investigate Further Let's not worry just yet about Medco's margins. |
The Motley Fool November 2, 2005 Brian Gorman |
Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note. |
The Motley Fool November 3, 2010 Brian Orelli |
A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it. |
The Motley Fool August 31, 2011 Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue. |
The Motley Fool July 30, 2009 Brian Orelli |
A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money. |
The Motley Fool June 30, 2005 Brian Gorman |
The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis. |
The Motley Fool November 9, 2005 Brian Gorman |
Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company. |
The Motley Fool August 1, 2008 Brian Orelli |
Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line. |
The Motley Fool August 29, 2007 Rich Duprey |
Medco's Potentially Perilous Purchase Is pharmacy-benefits manager Medco Health Solutions risking its own health by buying diabetes-testing supplier PolyMedica? The deal may end up being so expensive as to drain Medco's own performance. |
CFO June 1, 2010 Alix Stuart |
"This Is the Era of Smarter Medicine." A prescription-drug provider says it can thrive even as it helps drive down health-care costs. An interview with Richard Rubino, CFO, Medco Health Solutions Inc. |
PC Magazine August 19, 2003 Alan Cohen |
Online Prescriptions With $1.4 billion in sales last year, Merck subsidiary Medco Health online is doing something right. |
The Motley Fool September 27, 2006 Michael P. Cecil |
A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales. |
The Motley Fool October 5, 2010 Andrew Bond |
Wal-Mart Enters the Health-Care Fray Wal-Mart and Humana's partnership will have competitors scrambling. |
The Motley Fool August 16, 2010 Brian Orelli |
The Fine Line Between Saving Money and Making It Medco's trying to walk it. |
The Motley Fool February 14, 2005 Brian Gorman |
GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision. |
The Motley Fool June 22, 2006 Stephen D. Simpson |
Rite Aid: Not Quite Rad, but Not All Bad Better results are possible, but there might be better ideas for investors. |
Managed Care October 2003 |
Medco Health Solutions tops consumer survey The 2003 WilsonRx Survey reports that patients have identified Medco Health Solutions as the top pharmacy benefit manager for the third year in a row. |
The Motley Fool September 21, 2006 Nathan Parmelee |
Wal-Mart Goes Generic The supposed most terrible retailer of all is doing a very good thing with generic drug sales. The program will, of course, benefit Wal-Mart by creating additional traffic to its stores. This move could change the game for a number of retailers over the next few years. |
The Motley Fool October 28, 2010 |
Our Top Stock Idea Our investing community's latest prime pick -- Medco Health Solutions. |
Managed Care May 2006 |
Many More CDH Plans to Include Pharmacy The number of plan sponsors that will offer consumer-directed health plans that integrate pharmacy and medical benefits increased more than 16-fold, from 3 to 50, between January 2005 and January 2006, according to Medco Health Solutions. |
The Motley Fool February 22, 2005 Brian Gorman |
Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look. |
Managed Care December 2007 |
Insurers Lean Toward Generic Alternatives More insurers are focusing their attention on a second approach to generic drug management -- generic alternatives, which contain different active ingredients, but have comparable efficacy to brand-name drugs in the same class. |
The Motley Fool October 22, 2010 Roger Friedman |
3 Health-Care Stocks for Your Watchlist There's money to be made in health care. But finding the right plays, especially among health care providers, can prove confounding. |
The Motley Fool June 30, 2011 David Williamson |
Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split. |
The Motley Fool October 6, 2011 Dan Caplinger |
Has Medco Health Solutions Become the Perfect Stock? A lot has happened in the pharmacy benefits management space since we looked at Medco last year. |
Managed Care November 2007 Martin Sipkoff |
PBMs Agree to Disclose What They Pay for Drugs Pharmacy benefit managers will charge employers a straight administrative fee, rather than make much of their income through deals with the drug industry. |
The Motley Fool December 6, 2004 Brian Gorman |
Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors. |
The Motley Fool July 26, 2010 Jennifer Schonberger |
The S&P 500's Biggest Movers The index's most notable movers this week. |
Managed Care September 2007 |
Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs. |
The Motley Fool March 6, 2009 Brian Orelli |
Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now? |
Managed Care July 2007 |
The Formulary Files Chronic disease treatments contribute significantly to spending growth. |
The Motley Fool July 29, 2004 Brian Gorman |
Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look. |
The Motley Fool June 12, 2006 Brian Gorman |
Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note. |
Managed Care January 2007 Martin Sipkoff |
Employers Want Plans & PBMs To Push Hard for Generics Health insurers' aggressive stand on members' use of generic drugs can attract new clients, but does it interfere with the physician-patient relationship? |
The Motley Fool November 8, 2006 Selena Maranjian |
Yay Wal-Mart!? What readers are saying about Wal-Mart -- is it time for investors to listen? |
The Motley Fool March 22, 2010 Brian Orelli |
Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio. |
The Motley Fool August 15, 2007 Mary Dalrymple |
Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money. |
BusinessWeek May 9, 2005 Weintraub & Barrett |
BW 50: Can Caremark's Health Hold Up? Caremark Rx Inc. faces a growing set of legal and market challenges, but Its drug-benefit business is soaring, and its CEO remains upbeat about the future. |
The Motley Fool March 28, 2005 Brian Gorman |
A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities. |